{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T12:13:05Z","timestamp":1788178385866,"version":"build-2803163510"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T00:00:00Z","timestamp":1732838400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T00:00:00Z","timestamp":1732838400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"DOI":"10.1186\/s13045-024-01644-4","type":"journal-article","created":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T08:16:00Z","timestamp":1732868160000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["The first-in-class bispecific antibody IBI318 (LY3434172) targeting PD-1 and PD-L1 in patients with advanced tumors: a phase Ia\/Ib study"],"prefix":"10.1186","volume":"17","author":[{"given":"Dan-Yun","family":"Ruan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Li","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fu-Rong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi-Chun","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Mei","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ding-Zhi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-Qiu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Min","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wang-Jun","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun-Yu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Xiao","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Ling","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Yun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui-Hua","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,29]]},"reference":[{"key":"1644_CR1","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1146\/annurev-pathol-042020-042741","volume":"16","author":"S Bagchi","year":"2021","unstructured":"Bagchi S, Yuan R, Engleman EG. Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance. Annu Rev Pathol. 2021;16:223\u201349.","journal-title":"Annu Rev Pathol"},{"key":"1644_CR2","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12943-021-01489-2","volume":"21","author":"M Yi","year":"2022","unstructured":"Yi M, Zheng X, Niu M, Zhu S, Ge H, Wu K. Combination strategies with PD-1\/PD-L1 blockade: current advances and future directions. Mol Cancer. 2022;21:28.","journal-title":"Mol Cancer"},{"key":"1644_CR3","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s13045-022-01242-2","volume":"15","author":"M Wu","year":"2022","unstructured":"Wu M, Huang Q, Xie Y, Wu X, Ma H, Zhang Y, et al. Improvement of the anticancer efficacy of PD-1\/PD-L1 blockade via combination therapy and PD-L1 regulation. J Hematol Oncol. 2022;15:24.","journal-title":"J Hematol Oncol"},{"key":"1644_CR4","doi-asserted-by":"publisher","first-page":"3815","DOI":"10.1200\/JCO.2016.72.1167","volume":"35","author":"M Sznol","year":"2017","unstructured":"Sznol M, Ferrucci PF, Hogg D, Atkins MB, Wolter P, Guidoboni M, et al. Pooled analysis safety profile of nivolumab and ipilimumab combination therapy in patients with advanced melanoma. J Clin Oncol. 2017;35:3815\u201322.","journal-title":"J Clin Oncol"},{"key":"1644_CR5","doi-asserted-by":"publisher","first-page":"626616","DOI":"10.3389\/fimmu.2021.626616","volume":"12","author":"J Ma","year":"2021","unstructured":"Ma J, Mo Y, Tang M, Shen J, Qi Y, Zhao W, et al. Bispecific antibodies: from research to clinical application. Front Immunol. 2021;12:626616.","journal-title":"Front Immunol"},{"key":"1644_CR6","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1158\/2159-8290.CD-21-0257","volume":"11","author":"EM Burton","year":"2021","unstructured":"Burton EM, Tawbi HA. Bispecific antibodies to PD-1 and CTLA4: doubling down on T cells to decouple efficacy from toxicity. Cancer Discov. 2021;11:1008\u201310.","journal-title":"Cancer Discov"},{"issue":"18","key":"1644_CR7","doi-asserted-by":"publisher","first-page":"4035","DOI":"10.1158\/1078-0432.CCR-15-0612","volume":"21","author":"D Przepiorka","year":"2015","unstructured":"Przepiorka D, Ko CW, Deisseroth A, Yancey CL, Candau-Chacon R, Chiu HJ, Gehrke BJ, Gomez-Broughton C, Kane RC, Kirshner S, Mehrotra N. FDA approval: blinatumomab. Clin Cancer Res. 2015;21(18):4035\u20139.","journal-title":"Clin Cancer Res"},{"key":"1644_CR8","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1158\/1078-0432.CCR-23-3162","volume":"30","author":"H Lou","year":"2024","unstructured":"Lou H, Cai H, Huang X, Li G, Wang L, Liu F, et al. Cadonilimab combined with chemotherapy with or without bevacizumab a first-line treatment in recurrent or metastatic cervical cancer (COMPASSION-13): a phase 2 study. Clin Cancer Res. 2024;30:1501\u20138.","journal-title":"Clin Cancer Res"},{"key":"1644_CR9","unstructured":"Fang W, Zhao Y, Luo Y, Yang R, Huang Y, He Z, Zhao H, Li M, Li K, Song Q, Du X. Ivonescimab plus chemotherapy in non\u2013small cell lung cancer with EGFR variant: A Randomized Clinical Trial. JAMA. (2024)"},{"key":"1644_CR10","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s13045-023-01445-1","volume":"16","author":"Y Zhao","year":"2023","unstructured":"Zhao Y, Ma Y, Zang A, Cheng Y, Zhang Y, Wang X, et al. First-in-human phase I\/Ib study of QL1706 (PSB205), a bifunctional PD1\/CTLA4 dual blocker, in patients with advanced solid tumors. J Hematol Oncol. 2023;16:50.","journal-title":"J Hematol Oncol"},{"key":"1644_CR11","doi-asserted-by":"publisher","first-page":"e006654","DOI":"10.1136\/jitc-2022-006654","volume":"11","author":"Y Ma","year":"2023","unstructured":"Ma Y, Xue J, Zhao Y, Zhang Y, Huang Y, Yang Y, et al. Phase I trial of KN046, a novel bispecific antibody targeting PD-L1 and CTLA-4 in patients with advanced solid tumors. J Immunother Cancer. 2023;11:e006654.","journal-title":"J Immunother Cancer"},{"key":"1644_CR12","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1158\/1078-0432.CCR-22-1449","volume":"29","author":"TA Yap","year":"2023","unstructured":"Yap TA, LoRusso PM, Wong DJ, Hu-Lieskovan S, Papadopoulos KP, Holz J-B, et al. A phase 1 first-in-human study of FS118, a tetravalent bispecific antibody targeting LAG-3 and PD-L1 in patients with advanced cancer and PD-L1 resistance. Clin Cancer Res. 2023;29:888\u201398.","journal-title":"Clin Cancer Res"},{"issue":"328","key":"1644_CR13","doi-asserted-by":"publisher","first-page":"328rv4","DOI":"10.1126\/scitranslmed.aad7118","volume":"8","author":"W Zou","year":"2016","unstructured":"Zou W, Wolchok JD, Chen L. PD-L1 (B7\u2013H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations. Sci Transl Med. 2016;8(328):328rv4.","journal-title":"Sci Transl Med"},{"key":"1644_CR14","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41586-019-1593-5","volume":"574","author":"O Demaria","year":"2019","unstructured":"Demaria O, Cornen S, Da\u00ebron M, Morel Y, Medzhitov R, Vivier E. Harnessing innate immunity in cancer therapy. Nature. 2019;574:45\u201356.","journal-title":"Nature"},{"key":"1644_CR15","doi-asserted-by":"publisher","first-page":"3032","DOI":"10.1158\/1078-0432.CCR-21-4115","volume":"28","author":"MH Voss","year":"2022","unstructured":"Voss MH, Azad AA, Hansen AR, Gray JE, Welsh SJ, Song X, et al. A randomized phase II study of MEDI0680 in combination with durvalumab versus nivolumab monotherapy in patients with advanced or metastatic clear-cell renal cell carcinoma. Clin Cancer Res. 2022;28:3032\u201341.","journal-title":"Clin Cancer Res"},{"key":"1644_CR16","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1038\/s41416-022-02128-3","volume":"128","author":"J Desai","year":"2023","unstructured":"Desai J, Fong P, Moreno V, Frentzas S, Meniawy T, Markman B, et al. A Phase 1\/2 study of the PD-L1 inhibitor, BGB-A333, alone and in combination with the PD-1 inhibitor, tislelizumab, in patients with advanced solid tumours. Br J Cancer. 2023;128:1418\u201328.","journal-title":"Br J Cancer"},{"key":"1644_CR17","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1158\/2326-6066.CIR-20-0304","volume":"8","author":"H Kotanides","year":"2020","unstructured":"Kotanides H, Li Y, Malabunga M, Carpenito C, Eastman SW, Shen Y, et al. Bispecific targeting of PD-1 and PD-L1 enhances T-cell activation and antitumor immunity. Cancer Immunol Res. 2020;8:1300\u201310.","journal-title":"Cancer Immunol Res"},{"key":"1644_CR18","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.cct.2017.04.006","volume":"58","author":"W Guo","year":"2017","unstructured":"Guo W, Wang S-J, Yang S, Lynn H, Ji Y. A Bayesian interval dose-finding design addressingOckham\u2019s razor: mTPI-2. Contemp Clin Trials. 2017;58:23\u201333.","journal-title":"Contemp Clin Trials"},{"key":"1644_CR19","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1016\/S1470-2045(21)00333-8","volume":"22","author":"X Zhou","year":"2021","unstructured":"Zhou X, Yao Z, Bai H, Duan J, Wang Z, Wang X, et al. Treatment-related adverse events of PD-1 and PD-L1 inhibitor-based combination therapies in clinical trials: a systematic review and meta-analysis. Lancet Oncol. 2021;22:1265\u201374.","journal-title":"Lancet Oncol"},{"key":"1644_CR20","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1016\/S1470-2045(23)00411-4","volume":"24","author":"X Gao","year":"2023","unstructured":"Gao X, Xu N, Li Z, Shen L, Ji K, Zheng Z, et al. Safety and antitumour activity of cadonilimab, an anti-PD-1\/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b\/2 trial. Lancet Oncol. 2023;24:1134\u201346.","journal-title":"Lancet Oncol"},{"key":"1644_CR21","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck M, Rodr\u00edguez-Abreu D, Robinson AG, Hui R, Cs\u0151szi T, F\u00fcl\u00f6p A, et al. Pembrolizumab versus chemotherapy for PD-L1\u2013positive non\u2013small-cell lung cancer. N Engl J Med. 2016;375:1823\u201333.","journal-title":"N Engl J Med"},{"key":"1644_CR22","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.3390\/jcm10071365","volume":"10","author":"M Majem","year":"2021","unstructured":"Majem M, Cobo M, Isla D, Marquez-Medina D, Rodriguez-Abreu D, Casal-Rubio J, et al. PD-(L)1 inhibitors as monotherapy for the first-line treatment of non-small-cell lung cancer patients with high PD-L1 expression: a network meta-analysis. J Clin Med. 2021;10:1365.","journal-title":"J Clin Med"},{"key":"1644_CR23","doi-asserted-by":"publisher","first-page":"107355","DOI":"10.1016\/j.lungcan.2023.107355","volume":"184","author":"Y Zhao","year":"2023","unstructured":"Zhao Y, Ma Y, Fan Y, Zhou J, Yang N, Yu Q, et al. A multicenter, open-label phase Ib\/II study of cadonilimab (anti PD-1 and CTLA-4 bispecific antibody) monotherapy in previously treated advanced non-small-cell lung cancer (AK104-202 study). Lung Cancer. 2023;184:107355.","journal-title":"Lung Cancer"},{"key":"1644_CR24","doi-asserted-by":"publisher","first-page":"102428","DOI":"10.1016\/j.ctrv.2022.102428","volume":"109","author":"DR Adkins","year":"2022","unstructured":"Adkins DR, Haddad RI. Clinical trial data of Anti-PD-1\/PD-L1 therapy for recurrent or metastatic nasopharyngeal Carcinoma: a review. Cancer Treat Rev. 2022;109:102428.","journal-title":"Cancer Treat Rev"},{"key":"1644_CR25","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1158\/1078-0432.CCR-19-2337","volume":"26","author":"D Enrico","year":"2020","unstructured":"Enrico D, Paci A, Chaput N, Karamouza E, Besse B. Antidrug antibodies against immune checkpoint blockers: impairment of drug efficacy or indication of immune activation? Clin Cancer Res. 2020;26:787\u201392.","journal-title":"Clin Cancer Res"}],"container-title":["Journal of Hematology & Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-024-01644-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-024-01644-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-024-01644-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T09:11:13Z","timestamp":1732871473000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-024-01644-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,29]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1644"],"URL":"https:\/\/doi.org\/10.1186\/s13045-024-01644-4","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,29]]},"assertion":[{"value":"17 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol and all amendments were approved by the Institutional Review Boards of all participating institutions. All participants provided written informed consent. The study was performed in accordance with Good Clinical Practice guidelines and the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Xiao-Xiao Lu, Yu-Ling Chen, Wen Zhang, Hui Zhou are employees of Innovent Biologics (Suzhou) Co. Ltd. Rui-Hua Xu reports speaker fees from Bristol Myers Squibb, Roche, MerckSerono, Hutchison, Hengrui, Junshi, Qilu, CPPC, Henlius, and participates on advisory board for Astellas, MSD, AstraZeneca, Junshi, Hengrui, BeiGene. Innovent, CPPC, and Keymed.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"118"}}